Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

27.1%

16 terminated/withdrawn out of 59 trials

Success Rate

62.8%

-23.7% vs industry average

Late-Stage Pipeline

2 trials in Phase 3/4

Results Transparency

0 of 27 completed trials have results

Key Signals

8 recruiting13 terminated

Enrollment Performance

Analytics

N/A

31(59.6%)

Phase 2

15(28.8%)

Early Phase 1

2(3.8%)

Phase 1

2(3.8%)

Phase 3

1(1.9%)

Phase 4

1(1.9%)

52Total

N/A(31)

Phase 2(15)

Early Phase 1(2)

Phase 1(2)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (59)

Showing 20 of 59 trials

NCT03068663Not ApplicableActive Not Recruiting

Microbiota and the Lung Cancer

Role: lead

NCT04068623Active Not Recruiting

Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients

Role: lead

NCT06550674Not ApplicableRecruiting

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Role: lead

NCT04133077Not ApplicableRecruiting

Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer

Role: lead

NCT03020251Not ApplicableCompleted

Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer

Role: lead

NCT07361471Not ApplicableRecruiting

Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

Role: lead

NCT06600802Not ApplicableRecruiting

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Role: lead

NCT06512558Not ApplicableRecruiting

Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery

Role: lead

NCT04438681Active Not Recruiting

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients

Role: lead

NCT04503772Phase 2Completed

Preoperative Stereotactic Radiosurgery for Brain Metastases

Role: lead

NCT07178847Not ApplicableRecruiting

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Role: lead

NCT05157594Completed

hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors

Role: lead

NCT04273542Not ApplicableActive Not Recruiting

Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening

Role: lead

NCT05433077Active Not Recruiting

Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment

Role: lead

NCT05710679Not ApplicableRecruiting

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Role: lead

NCT06062199Not ApplicableRecruiting

Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt

Role: lead

NCT04881032Phase 1Active Not Recruiting

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

Role: lead

NCT03401840Not ApplicableCompleted

STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Role: lead

NCT03784625Early Phase 1Completed

Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012

Role: lead

NCT04481230Early Phase 1Completed

Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer

Role: lead